Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2

Conditions

Wilms Tumor 4Rhabdoid Tumor 4Neuroectodermal Tumors, Primitive, Peripheral 4Neuroblastoma 4Medulloblastoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Sarcoma 3Rhabdomyosarcoma 3Osteosarcoma 3Multiple Myeloma 3Central Nervous System Neoplasms 3Sarcoma, Ewing 2Xanthogranuloma, Juvenile 1Histiocytic Sarcoma 1Familial ependymoma 1

Interventions

Irinotecan 6Temozolomide 5Cyclophosphamide 5Vincristine 4Magnetic Resonance Spectroscopy 4Doxorubicin 4palbociclib 3X-Rays 3Phantoms, Imaging 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ganitumab 2eribulin 2cixutumumab 2cabozantinib 2abemaciclib 2Vemurafenib 2Specimen Handling 2Radiotherapy, Image-Guided 2Radiosurgery 2Peripheral Blood Stem Cell Transplantation 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2FANG vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Sarcoma, Ewing × Nuclear Medicine Department, Hospital × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1 enrolled 3 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡